Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$293.74 0.87 (0.30)%

High 295.57 Low 292.50 Volume 637,628 Market Cap 31.12B
05/25/18 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • May 21

    New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma

    Read on
  • May 18

    Regeneron Announces Upcoming Investor Conference Presentation

    Read on

EVENTS

  • Barclays 2018 Biopharmaceuticals CEO/CFO Conference Call Series
    Jun 1, 2018 | 11:00 AM ET

  • 2018 Annual Meeting of Shareholders
    Jun 8, 2018 | 10:30 AM ET

Events & Presentations

NASDAQ REGN

$293.74 0.87 (0.30)%

High 295.57 Low 292.50 Volume 637,628 Market Cap 31.12B
05/25/18 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information